Secondary cancer and relapse rates following radical prostatectomy for prostate-confined cancer.
In the SEER database, it is relatively easy to identify secondary cancers that follow an initial diagnosis of cancer. However, the SEER public-use data does not explicitly capture relapse of the initial cancer. One can assume that organ-confined prostate cancer treated by radical prostatectomy will show no evidence of disease after treatment. Death due to prostate cancer in such cases can be assumed to follow a relapse of previously occult metastatic disease. We devised an estimate of the timing of these relapses and tabulated rates for both new primaries and relapses following radical prostatectomy for organ-confined prostate cancer.
Transamerica Reinsurance, 401 North Tryon Street, Suite 700, Charlotte, NC 28202, USA. david.wesley.md@transamerica.com
David
D
Wesley
Hugh F
HF
Cox
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000473:pathology; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000473:pathology; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery*; D018426:SEER Program; D014481:United States / Q000453:epidemiology